Chad Miller, MD
Pulmonary Disease · Austell, GANPI 1538373071
Payments from drug & device makers
Across 970 payments — averaging $2053.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$904K
- Merck$362K
- Janssen Research & Development, LLC$204K
- Actelion Pharmaceuticals US, Inc.$157K
- Actelion Pharmaceuticals, Ltd$156K
- Insmed, Inc.$152K
- plus $57K from 32 others
What the payments were for
- Consulting fees$60,71816%
- Speaking & faculty fees$260,63268%
- Travel & lodging$38,85810%
- Food & beverage$21,5576%
- Education$1070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 359 | $904,253 |
| Merck | 32 | $361,585 |
| Janssen Research & Development, LLC | 66 | $204,147 |
| Actelion Pharmaceuticals US, Inc. | 217 | $157,271 |
| Actelion Pharmaceuticals, Ltd | 30 | $156,364 |
| Insmed, Inc. | 64 | $151,812 |
| Bayer | 74 | $46,084 |
| Chiesi USA, Inc. | 8 | $8,497 |
| AstraZeneca(2 entities) | 19 | $435 |
| GSK | 28 | $380 |
| Sandoz | 15 | $267 |
| Boehringer Ingelheim | 5 | $117 |
| EKOS Corporation | 1 | $112 |
| Johnson & Johnson(2 entities) | 10 | $100 |
| Baxter Healthcare | 1 | $98 |
| Pfizer | 5 | $91 |
| Sunovion Pharmaceuticals Inc. | 4 | $75 |
| Teva Pharmaceuticals USA, Inc. | 4 | $66 |
| Grifols USA, LLC | 2 | $56 |
| Jazz Pharmaceuticals Inc. | 2 | $56 |
| Novartis | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Philips North America LLC | 2 | $39 |
| Amgen | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Edwards Lifesciences | 1 | $35 |
| Covis Pharma GmbH | 2 | $34 |
| Teleflex LLC | 1 | $34 |
| Vapotherm Inc | 1 | $27 |
| Circassia Inc. | 1 | $24 |
| Pulmonx Corporation | 1 | $24 |
| Mallinckrodt Enterprises LLC | 1 | $24 |
| Sanofi | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $17 |
| Electromed, Inc. | 1 | $16 |
| Gilead | 1 | $15 |
| Resmed Corp | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,992,373 in reported general payments places this provider in the 95th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 251 | $3,467,944 |
| UptraviSelexipag | 135 | $3,036,233 |
| OpsumitMacitentan | 233 | $2,965,617 |
| Tyvaso DpiTreprostinil | 69 | $1,629,647 |
| Orenitram ErTreprostinil Diolamine | 73 | $930,072 |
| LetairisAmbrisentan | 43 | $647,463 |
| WinrevairSotatercept-Csrk | 22 | $307,108 |
| Ambrisentan | 83 | $238,959 |
| AdcircaTadalafil | 38 | $209,174 |
| OpsynviMacitentan/Tadalafil | 12 | $138,393 |
| Tadalafil | 147 | $124,090 |
| EliquisApixaban | 74 | $49,259 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $38,818 |
| Bosentan | 15 | $27,515 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 37 | $18,567 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit, Opsynvi, Bosentan | $157,271 | $6,167,758395 claims |
| BayerAdempas | $46,084 | $3,467,944251 claims |
| GileadLetairis | $15 | $647,46343 claims |
| MerckWinrevair | $361,585 | $307,10822 claims |
| United Therapeutics CorporationAdcirca | $904,253 | $209,17438 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $380 | $69,964128 claims |
| PfizerEliquis | $91 | $49,25974 claims |
| Boehringer IngelheimStiolto Respimat | $117 | $16,54922 claims |
| Johnson & JohnsonXarelto | $100 | $9,84412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Austell
- Amy CaseAustell$1.5M
- Sriram ParameshAustell$36K
- Steven HarrisAustell$35K
- Maria MascoloRincon$2.7M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
- Vijay PatelNewnan$1.1M
- Lawrence McDermottSavannah$963K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.